PTO/SB/08a (05-07)
Approved for use through 09/30/2007 OMB 0851-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
(,

Application Number Filing Date		10535445 2006-10-31		
Art Unit		1652		
Examiner Name	PROUTY, REBECCA E.			
Attorney Docket Number		05-1042-B5 (EX03-087C-US)		

					U.S.	PATENTS			Remove		
Examiner Initial*	niner Cite No Patent Number Kind Code1 Issue Date		Date	Name of Patentee or Applicant R			Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear				
	1										
If you wisl	h to a	id additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	n Name of Patentee or Applicant of cited Document				Lines where ges or Relev	
	1										
If you wisl	h to a	dd additional U.S. Publi						d button	=		
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³			Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	vhere Rel	or Relevant	т.	
	1										
If you wis	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	1-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Initials* Cite Initials* No publisher, city and/or country where published.									Τs		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10535445			
iling Date		2006-10-31			
irst Named Inventor	Lisa C	Lisa C. Kadyk			
rt Unit		1652			
xaminer Name	PROL	PROUTY, REBECCA E.			
ttornev Docket Number		05-1042-B5 (EX03-087C-US)			

	1	Ulloa, L. et al.; "Depletion of casen Kinase II by Anlisense Oligonucleotide Prevents Neurologenesis in Neuroblastoma Cells," EMBO Journal, Oxford University Press, Surrey, GB, VoRt 12, No. 4, January 1, 1993, pages 1833-1840	
	2	Munsterman, U. et al.: "Casein kinase II is elevated in solid human humors and rapidly proliferating non-neoplastic tissue," European Journal of biochemistry, Berlin, Vol. 189, No. 2, April 30, 1990, pages 251-257.	
	3	MoKey, R. M. et al.: "The casein kinase I family in Whit signaling," Developmental Biology, Academic Press, New York, NY, US, Vol. 235, No. 2, July 15, 2007, pages 389-396.	
	4	Weir, H. M. et al.: "Human kappa-casein as a lumor marker: purification and properties," Cancer Detection and Prevention 1891, Vol. 4, No. 1-4, 1981, pages 193-294.	
	5	Cohen, C. et al.: "Tumor-associated antigens in breast carcinomas. Prognostio significance," CANCER, September 15, 1987, Vol. 60, No. 6, pages 1294-1298.	
	6	Pepperkok, R. et al.: "Cell Growth Stimulation by EGF. Inhibition Through Antisense-Oligodeoxynucleolide Demonstrates Important Role of Casein Knase II," Experimental Cell Research, San Dego, CA, US, Vol. 197, January 1991, pages 245-253.	
If you	wish to a	dd additional non-patent literature document citation information please click the Add button Add	_

A

E

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Patent Documents at Invest USPTO GOV; or MPEP 90.04. Esters dotic that issued the document, by the two lefters of Kind Wilder Standard ST3.) For Supersee patent for counters, the endoated on the year of the register of the Empiorary management are useful replicated for the Empiorary management are useful replicated for the Empiorary management and the Empirity of the Empirit